InspireMD (NSPR) : 1 analysts are covering InspireMD (NSPR) and their average rating on the stock is 1, which is read as a Strong Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.
InspireMD (NYSEMKT:NSPR): The stock opened in the green at $0.11 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.1178 and a low of $0.11 for the day. The stock did not find buyers even at the lows and closed at $0.11 recording a loss of -3.51%. 819,696 shares exchanged hands during the trading day. The stock had closed at $0.114 in the previous days trading.
InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.